The Initial and Midterm Clinical Outcome of Paclitaxel-eluting-stent (Zilver PTX) for the Femoropopliteal Arteries

Abstract

We investigated the initial and midterm outcomes of Zilver PTX, which was approved in Japan for the first time. Patient population was the all-comer (71 patients, 81 limbs), which included 54.3% on hemodialysis, 58% of severe calcification, 61.7% of TASC D lesions and average lesion length was 204.7 ± 97.7 mm. MALE free ratios revealed 85.1% at 6 months and 70.1% at 1 year. Considering the study population which involved more than 50% of TASC D and hemodialysis patients, the initial and midterm clinical outcomes of Zilver PTX were feasible enough.